Dyne Therapeutics Shares Surge 10% on Investor Conference Call Announcement
Dyne Therapeutics, a biotechnology company, saw its shares rise by up to 10% after the market closed on Wednesday following an announcement regarding an investor conference call to review new clinical data. The company is set to review data from its ACHIEVE trial, a study focused on an undisclosed treatment, on January 10. Details on the nature of the trial or the data to be reviewed have not been provided. As a specialist in developing therapies for patients with serious muscle diseases, Dyne Therapeutics is generating excitement among investors ahead of the review.